Zobrazeno 1 - 10
of 188
pro vyhledávání: '"Mirza, MR"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
du Bois, A, Kristensen, G, Ray-Coquard, I, Reuss, A, Pignata, S, Colombo, N, Denison, U, Vergote, I, Del Campo JM, Ottevanger, P, Heubner, M, Minarik, T, Sevin, E, de Gregorio, N, Bidziński, M, Pfisterer, J, Malander, S, Hilpert, F, Mirza, Mr, Scambia, G, Meier, W, Nicoletto, Mo, Bjørge, L, Lortholary, A, Sailer, Mo, Merger, M, Harter, P, AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium: Università degli Studi di Torino ITA, Ferrero, A, Et, Al
Publikováno v:
Lancet Oncology, 17, 1, pp. 78-89
du Bois, A, Kristensen, G, Ray-Coquard, I, Reuss, A, Pignata, S, Colombo, N, Denison, U, Vergote, I, Del Campo, J M, Ottevanger, P, Heubner, M, Minarik, T, Sevin, E, de Gregorio, N, Bidziński, M, Pfisterer, J, Malander, S, Hilpert, F, Mirza, M R, Scambia, G, Meier, W, Nicoletto, M O, Bjørge, L, Lortholary, A, Sailer, M O, Merger, M, Harter, P & AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium 2016, ' Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12) : a randomised, double-blind, placebo-controlled phase 3 trial ', Lancet Oncology, vol. 17, no. 1, pp. 78-89 . https://doi.org/10.1016/S1470-2045(15)00366-6
Lancet Oncology, 17, 78-89
du Bois, A, Kristensen, G, Ray-Coquard, I, Reuss, A, Pignata, S, Colombo, N, Denison, U, Vergote, I, Del Campo, J M, Ottevanger, P, Heubner, M, Minarik, T, Sevin, E, de Gregorio, N, Bidziński, M, Pfisterer, J, Malander, S, Hilpert, F, Mirza, M R, Scambia, G, Meier, W, Nicoletto, M O, Bjørge, L, Lortholary, A, Sailer, M O, Merger, M, Harter, P & AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium 2016, ' Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12) : a randomised, double-blind, placebo-controlled phase 3 trial ', Lancet Oncology, vol. 17, no. 1, pp. 78-89 . https://doi.org/10.1016/S1470-2045(15)00366-6
Lancet Oncology, 17, 78-89
BACKGROUND: Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::978a413fe8167ddba627ac3f70a6cc68
https://doi.org/10.1016/s1470-2045(15)00366-6
https://doi.org/10.1016/s1470-2045(15)00366-6
Autor:
Wilson, MK, Pujade-Lauraine, E, Aoki, D, Mirza, MR, Lorusso, D, Oza, AM, du Bois, A, Vergote, Ignace, Reuss, A, Bacon, M, Friedlander, M, Rincon, D, Joly, F, Chang, S-J, Ferrero, AM, Edmondson, RJ, Wimberger, P, Maenpaa, J, Gaffney, D, Zhang, R, Okamoto, A, Stuart, G, Ochiai, K
This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the 5th Ovarian Cancer Consensus Conference (OCCC), which was held in Tokyo, Japan, in November 2015. Three important questions were identified: (1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1131::23692d185ff7d8b3721f7457b08e9e33
https://lirias.kuleuven.be/handle/123456789/562999
https://lirias.kuleuven.be/handle/123456789/562999
Autor:
Oza, AM, Cook, AD, Pfisterer, J, Embleton, A, Ledermann, JA, Pujade-Lauraine, E, Kristensen, G, Carey, MS, Beale, P, Cervantes, A, Park-Simon, T-W, Rustin, G, Joly, F, Mirza, MR, Plante, M, Quinn, M, Poveda, A, Jayson, GC, Stark, D, Swart, AM, Farrelly, L, Kaplan, R, Parmar, MKB, Perren, TJ
Publikováno v:
Oza, A M, Cook, A D, Pfisterer, J, Embleton, A, Ledermann, J A, Pujade-Lauraine, E, Kristensen, G, Carey, M S, Beale, P, Cervantes, A, Park-Simon, T-W, Rustin, G, Joly, F, Mirza, M R, Plante, M, Quinn, M S, Poveda, A, Jayson, G C, Stark, D, Swart, A M, Farrelly, L, Kaplan, R, Parmar, M K B, Perren, T J & ICON7 trial investigators 2015, ' Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7) : overall survival results of a phase 3 randomised trial ', Lancet Oncology, vol. 16, no. 8, pp. 928-936 . https://doi.org/10.1016/S1470-2045(15)00086-8
BACKGROUND: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::8dee481155bef518cb7d7907f28f5f8f
https://vbn.aau.dk/da/publications/eb7eb733-cabd-47b8-b97c-4c9966777fa3
https://vbn.aau.dk/da/publications/eb7eb733-cabd-47b8-b97c-4c9966777fa3
Autor:
Perren, TJ, Swart, AM, Pfisterer, J, Ledermann, JA, Pujade-Lauraine, E, Kristensen, G, Carey, MS, Beale, P, Cervantes, A, Kurzeder, C, du Bois, A, Sehouli, J, Kimmig, R, Stähle, A, Collinson, F, Essapen, S, Gourley, C, Lortholary, A, Selle, F, Mirza, MR, Leminen, A, Plante, M, Stark, D, Qian, W, Parmar, MKB, Oza, AM
Background: Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease.\ud \ud \ud \ud Methods: We randomly assigned wome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::efdbb9307badebae27497b45acfb3862
https://doi.org/10.5167/uzh-59057
https://doi.org/10.5167/uzh-59057
Autor:
Lajer, Henrik, Jensen, Mette B., Kilsmark, Jannie, Albæk, Jens, Svane, Danny, Mirza, MR, Geertsen, Poul Flemming, Reerman, Diana, Hansen, Kåre, Milter, Maya C, Mogensen, Ole
Publikováno v:
Lajer, H, Jensen, M B, Kilsmark, J, Albæk, J, Svane, D, Mirza, MR, Geertsen, P F, Reerman, D, Hansen, K, Milter, M C & Mogensen, O 2010, ' The value of gynecologic cancer follow-up : Evidence-based ignorance? ', International Journal of Gynecological Cancer, vol. 20, no. 8, pp. 1307-20 . https://doi.org/10.1111/IGC.0b013e3181f3bee0
INTRODUCTION:: To explore the extent of evidence-based data and cost-utility of follow-up after primary treatment of endometrial and ovarian cancer, addressing perspectives of technology, organization, economics, and patients. METHODS:: Systematic li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3062::26e0c04db2119f6c248d754db8102259
https://portal.findresearcher.sdu.dk/da/publications/b8d926df-f4e5-4340-b0bf-8a06c37c366b
https://portal.findresearcher.sdu.dk/da/publications/b8d926df-f4e5-4340-b0bf-8a06c37c366b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza MR, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes RJ
Publikováno v:
JNCI: Journal of the National Cancer Institute; Sep2011, Vol. 103 Issue 17, p1338-1342, 5p